stoxline Quote Chart Rank Option Currency Glossary
  
Scilex Holding Company (SCLX)
4.79  -0.03 (-0.62%)    06-16 16:00
Open: 4.82
High: 4.97
Volume: 101,754
  
Pre. Close: 4.82
Low: 4.71
Market Cap: 33(M)
Technical analysis
2025-06-16 4:41:08 PM
Short term     
Mid term     
Targets 6-month :  7.17 1-year :  8.78
Resists First :  6.14 Second :  7.51
Pivot price 5.57
Supports First :  3.92 Second :  3.26
MAs MA(5) :  5.28 MA(20) :  5.36
MA(100) :  8.34 MA(250) :  24.96
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  14.5 D(3) :  25.8
RSI RSI(14): 42.9
52-week High :  78.05 Low :  0.36
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SCLX ] has closed above bottom band by 20.2%. Bollinger Bands are 47.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5 - 5.05 5.05 - 5.08
Low: 4.61 - 4.67 4.67 - 4.71
Close: 4.72 - 4.82 4.82 - 4.88
Company Description

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Headline News

Thu, 05 Jun 2025
Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal - GlobeNewswire

Fri, 16 May 2025
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - GlobeNewswire

Wed, 30 Apr 2025
Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule - GlobeNewswire

Wed, 30 Apr 2025
Scilex Holding Company Regains Compliance with Nasdaq Minimum Closing Bid Price Requirement - Nasdaq

Wed, 16 Apr 2025
Scilex Holding Company Announces FDA Has Approved Our - GlobeNewswire

Fri, 11 Apr 2025
Scilex Holding Company Announces 1-for-35 Reverse Stock Split - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Shares Out 5 (M)
Shares Float 5 (M)
Held by Insiders 22.3 (%)
Held by Institutions 18.7 (%)
Shares Short 297 (K)
Shares Short P.Month 241 (K)
Stock Financials
EPS -15.28
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -38.5
Profit Margin -147 %
Operating Margin -557.6 %
Return on Assets (ttm) -69.3 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth -54 %
Gross Profit (p.s.) 6.64
Sales Per Share 9.23
EBITDA (p.s.) -16.45
Qtrly Earnings Growth 0 %
Operating Cash Flow 16 (M)
Levered Free Cash Flow 43 (M)
Stock Valuations
PE Ratio -0.32
PEG Ratio 0
Price to Book value -0.13
Price to Sales 0.51
Price to Cash Flow 1.64
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android